Cardiovascular risks associated with diabetes are a concern for patients, healthcare professionals and payers. However, following recent clinical trial results for two Novo Nordisk GLP-1 analogues, hopes for improved treatment outcomes are growing.
The US is by far Novo Nordisk’s largest market, accounting for approximately half of the company’s total sales. It is a hugely complex healthcare market that is changing rapidly. For Novo Nordisk, this means challenges and opportunities ahead.
2016 was a year of significant changes for Novo Nordisk, including from a risk management perspective. Some risks emerged faster and with a higher impact than expected, while others all but disappeared from Novo Nordisk’s risk ‘heat map’.